A non-genetic model for type 2 diabetic nephropathy was developed and validated.
AT1R and AT2R antagonists’ effects were studied on NF-κB activity and ACE2.
We found that the activation of NF-κB signalling pathway is mediated through AT1R.
The blockade of AT2R was found to upregulate ACE2 expression.